BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Colombel JF, Keir ME, Scherl A, Zhao R, de Hertogh G, Faubion WA, Lu TT. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut 2017;66:2063-8. [PMID: 27590995 DOI: 10.1136/gutjnl-2016-312307] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Golovics PA, Gonczi L, Reinglas J, Verdon C, Pundir S, Afif W, Wild G, Bitton A, Bessissow T, Lakatos PL. Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study. Dig Dis Sci 2021. [PMID: 34286411 DOI: 10.1007/s10620-021-07178-w] [Reference Citation Analysis]
2 Revés J, Ungaro RC, Torres J. Unmet needs in inflammatory bowel disease. Curr Res Pharmacol Drug Discov 2021;2:100070. [PMID: 34988431 DOI: 10.1016/j.crphar.2021.100070] [Reference Citation Analysis]
3 Restellini S, Lakatos PL. Patient-Reported Outcomes in Inflammatory Bowel Diseases: Another Piece in the Puzzle. J Crohns Colitis 2021;15:1085-6. [PMID: 33515244 DOI: 10.1093/ecco-jcc/jjaa261] [Reference Citation Analysis]
4 Pai RK, Khanna R, D’haens GR, Sandborn WJ, Jeyarajah J, Feagan BG, Vande Casteele N, Jairath V. Definitions of response and remission for the Robarts Histopathology Index. Gut 2019;68:2101-2. [DOI: 10.1136/gutjnl-2018-317547] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
5 Dulai PS, Singh S, Jairath V, Ma C, Narula N, Vande Casteele N, Peyrin-Biroulet L, Vermeire S, D'Haens G, Feagan BG, Sandborn WJ. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Aliment Pharmacol Ther 2020;51:435-45. [PMID: 31755121 DOI: 10.1111/apt.15577] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
6 Boland K, Bedrani L, Turpin W, Kabakchiev B, Stempak J, Borowski K, Nguyen G, Steinhart AH, Smith MI, Croitoru K, Silverberg MS. Persistent Diarrhea in Patients With Crohn's Disease After Mucosal Healing Is Associated With Lower Diversity of the Intestinal Microbiome and Increased Dysbiosis. Clin Gastroenterol Hepatol. 2020;. [PMID: 32220613 DOI: 10.1016/j.cgh.2020.03.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Pérez de Arce E, Quera R, Quigley EMM. The Dilemma of Persistent Irritable Bowel Syndrome Symptoms in Patients with Quiescent Inflammatory Bowel Disease. Gastroenterol Clin North Am 2021;50:689-711. [PMID: 34304795 DOI: 10.1016/j.gtc.2021.03.008] [Reference Citation Analysis]
8 Dal Buono A, Roda G, Argollo M, Paridaens K, Peyrin-Biroulet L, Danese S. 'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. Curr Drug Targets 2021;22:117-25. [PMID: 32718289 DOI: 10.2174/1389450121666200727120305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Sandborn WJ, Nguyen DD, Beattie DT, Brassil P, Krey W, Woo J, Situ E, Sana R, Sandvik E, Pulido-Rios MT, Bhandari R, Leighton JA, Ganeshappa R, Boyle DL, Abhyankar B, Kleinschek MA, Graham RA, Panes J. Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme. J Crohns Colitis 2020;14:1202-13. [PMID: 32161949 DOI: 10.1093/ecco-jcc/jjaa049] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
10 Stalgis C, Deepak P, Mehandru S, Colombel JF. Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease. Gastroenterology 2021;161:394-9. [PMID: 33961886 DOI: 10.1053/j.gastro.2021.04.068] [Reference Citation Analysis]
11 Goll R, Heitmann R, Moe ØK, Carlsen K, Florholmen J. Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis. PLoS One 2019;14:e0224895. [PMID: 31790426 DOI: 10.1371/journal.pone.0224895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lobatón T, Bessissow T, Ruiz-Cerulla A, De Hertogh G, Bisschops R, Guardiola J, Van Assche G, Vermeire S, Ferrante M. Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter study. United European Gastroenterol J 2018;6:765-72. [PMID: 30083339 DOI: 10.1177/2050640617752207] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
13 Ooi CJ, Hilmi IN, Kim HJ, Jalihal U, Wu DC, Demuth D, Lindner D, Adsul S. Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study. Intest Res 2021;19:71-82. [PMID: 32877600 DOI: 10.5217/ir.2019.09159] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Pai RK, Jairath V, Vande Casteele N, Rieder F, Parker CE, Lauwers GY. The emerging role of histologic disease activity assessment in ulcerative colitis. Gastrointestinal Endoscopy 2018;88:887-98. [DOI: 10.1016/j.gie.2018.08.018] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
15 Ma C, Sedano R, Almradi A, Casteele NV, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R, Sands BE, Rosty C, Dubinsky MC, Rieder F, Harpaz N, Abreu MT, Bryant RV, Lauwers GY, Kirsch R, Valasek MA, Crowley E, Sandborn WJ, Feagan BG, Pai RK, Jairath V. An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. Gastroenterology 2021;160:2291-302. [PMID: 33610533 DOI: 10.1053/j.gastro.2021.02.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
16 Rowan CR, Keegan D, Byrne K, Cullen G, Mulcahy HE, Sheridan J, Ryan EJ, de Vries A, D'haens G, Doherty GA. Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. Aliment Pharmacol Ther 2018;48:333-9. [DOI: 10.1111/apt.14834] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
17 de Jong MJ, Huibregtse R, Masclee AAM, Jonkers DMAE, Pierik MJ. Patient-Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases: A Systematic Review. Clin Gastroenterol Hepatol 2018;16:648-663.e3. [PMID: 29074448 DOI: 10.1016/j.cgh.2017.10.019] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 9.2] [Reference Citation Analysis]
18 Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further? Expert Rev Gastroenterol Hepatol 2020;14:807-17. [PMID: 32762582 DOI: 10.1080/17474124.2020.1804361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Ma C, Sandborn WJ, D'Haens GR, Zou G, Stitt LW, Singh S, Ananthakrishnan AN, Dulai PS, Khanna R, Jairath V, Feagan BG. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2020;18:1760-1768.e1. [PMID: 31546056 DOI: 10.1016/j.cgh.2019.09.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
20 Nam K, Park SH, Oh JH, Lee HS, Noh S, Park JC, Kim JY, Oh EH, Kim J, Ham NS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK. Prevalence and risk factors of bowel symptoms in Korean patients with ulcerative colitis in endoscopic remission: a retrospective study. BMC Gastroenterol 2021;21:13. [PMID: 33407193 DOI: 10.1186/s12876-020-01597-1] [Reference Citation Analysis]
21 Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V. Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. Clin Gastroenterol Hepatol 2020;18:424-431.e7. [PMID: 31108227 DOI: 10.1016/j.cgh.2019.05.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570-83. [PMID: 33359090 DOI: 10.1053/j.gastro.2020.12.031] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 51.0] [Reference Citation Analysis]
23 Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2017;15:1427-1434.e2. [PMID: 28365485 DOI: 10.1016/j.cgh.2017.03.032] [Cited by in Crossref: 113] [Cited by in F6Publishing: 106] [Article Influence: 22.6] [Reference Citation Analysis]
24 Scheibe K, Kersten C, Schmied A, Vieth M, Primbs T, Carlé B, Knieling F, Claussen J, Klimowicz AC, Zheng J, Baum P, Meyer S, Schürmann S, Friedrich O, Waldner MJ, Rath T, Wirtz S, Kollias G, Ekici AB, Atreya R, Raymond EL, Mbow ML, Neurath MF, Neufert C. Inhibiting Interleukin 36 Receptor Signaling Reduces Fibrosis in Mice With Chronic Intestinal Inflammation. Gastroenterology 2019;156:1082-1097.e11. [DOI: 10.1053/j.gastro.2018.11.029] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 19.3] [Reference Citation Analysis]
25 Agrawal M, Colombel JF. Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat? Gastrointest Endosc Clin N Am. 2019;29:421-436. [PMID: 31078245 DOI: 10.1016/j.giec.2019.02.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
26 Colombel JF, Shin A, Gibson PR. Reply. Clin Gastroenterol Hepatol 2019;17:573-4. [PMID: 30678842 DOI: 10.1016/j.cgh.2018.08.073] [Reference Citation Analysis]
27 Cushing KC, Tan W, Alpers DH, Deshpande V, Ananthakrishnan AN. Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. Aliment Pharmacol Ther 2020;51:347-55. [PMID: 31696961 DOI: 10.1111/apt.15568] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
28 Narula N, Alshahrani A, Yuan Y, Reinisch W, Colombel J. Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2019;17:411-418.e3. [DOI: 10.1016/j.cgh.2018.06.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
29 Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1028-35. [PMID: 30365009 DOI: 10.1093/ibd/izy323] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
30 Ventin-Holmberg R, Eberl A, Saqib S, Korpela K, Virtanen S, Sipponen T, Salonen A, Saavalainen P, Nissilä E. Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:1019-31. [PMID: 33300552 DOI: 10.1093/ecco-jcc/jjaa252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Fluxá D, Simian D, Flores L, Ibáñez P, Lubascher J, Figueroa C, Kronberg U, Pizarro G, Castro M, Piottante A, Vial MT, Quera R. Clinical, endoscopic and histological correlation and measures of association in ulcerative colitis: Correlation in ulcerative colitis. Journal of Digestive Diseases 2017;18:634-41. [DOI: 10.1111/1751-2980.12546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
32 Ichikawa R, Lamb CA, Eastham-Anderson J, Scherl A, Raffals L, Faubion WA, Bennett MR, Long AK, Mansfield JC, Kirby JA, Keir ME. AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation. J Crohns Colitis 2018;12:1191-9. [PMID: 29912405 DOI: 10.1093/ecco-jcc/jjy084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
33 Sedano R, Jairath V, Ma C; IBD Trial Design Group. Design of Clinical Trials for Mild to Moderate Ulcerative Colitis. Gastroenterology 2022;162:1005-18. [PMID: 34998800 DOI: 10.1053/j.gastro.2021.12.284] [Reference Citation Analysis]
34 Panés J, Vermeire S. JAK Inhibitors: Back to Small Molecules for the Treatment of IBD. J Crohns Colitis 2020;14:S711-2. [PMID: 32737980 DOI: 10.1093/ecco-jcc/jjaa109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Yang RX, Song WJ, Wu ZQ, Goyal H, Xu HG. Association of Serum Neuron-Specific Enolase and C-Reactive Protein With Disease Location and Endoscopic Inflammation Degree in Patients With Crohn's Disease. Front Med (Lausanne) 2021;8:663920. [PMID: 34513858 DOI: 10.3389/fmed.2021.663920] [Reference Citation Analysis]
36 Chateau T, Feakins R, Marchal-Bressenot A, Magro F, Danese S, Peyrin-Biroulet L. Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure.Am J Gastroenterol. 2020;115:179-189. [PMID: 31809296 DOI: 10.14309/ajg.0000000000000437] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
37 Wehkamp J, Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Res 2018;7:F1000 Faculty Rev-1207. [PMID: 30135722 DOI: 10.12688/f1000research.15159.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
38 Tsuda S, Kunisaki R, Kato J, Murakami M, Nishio M, Ogashiwa T, Yoshida T, Kimura H, Kitano M. Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis. Intest Res 2018;16:579-87. [PMID: 30301332 DOI: 10.5217/ir.2018.00021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
39 Dragasevic S, Sokic-Milutinovic A, Stojkovic Lalosevic M, Milovanovic T, Djuranovic S, Jovanovic I, Rajic S, Stojkovic M, Milicic B, Kmezic S, Oluic B, Aleksic M, Pavlovic Markovic A, Popovic D. Correlation of Patient-Reported Outcome (PRO-2) with Endoscopic and Histological Features in Ulcerative Colitis and Crohn's Disease Patients. Gastroenterol Res Pract 2020;2020:2065383. [PMID: 32328091 DOI: 10.1155/2020/2065383] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Dulai PS, Peyrin-Biroulet L. Integrating Patient-Reported Outcomes Into Treat-to-Target Monitoring Algorithms. Clin Gastroenterol Hepatol 2019;17:395-6. [PMID: 30153519 DOI: 10.1016/j.cgh.2018.08.060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
41 Boal Carvalho P, Cotter J. Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. Drugs. 2017;77:159-173. [PMID: 28078646 DOI: 10.1007/s40265-016-0676-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
42 Salem MS, Melmed GY. The Role of Histology in Determining Disease Activity, Treatment, and Prognosis: Are We There yet? Gastrointest Endosc Clin N Am 2019;29:437-46. [PMID: 31078246 DOI: 10.1016/j.giec.2019.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
43 Mak LY, Tong TSM, Cheung KS, Chen LJ, Lui KL, Lau KS, Leung WK. Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2020;11:e00138. [PMID: 32132451 DOI: 10.14309/ctg.0000000000000138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
44 Lu PD, Zhao YH. Targeting NF-κB pathway for treating ulcerative colitis: comprehensive regulatory characteristics of Chinese medicines. Chin Med 2020;15:15. [PMID: 32063999 DOI: 10.1186/s13020-020-0296-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
45 Verstockt B, Verstockt S, Dehairs J, Ballet V, Blevi H, Wollants WJ, Breynaert C, Van Assche G, Vermeire S, Ferrante M. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. EBioMedicine 2019;40:733-42. [PMID: 30685385 DOI: 10.1016/j.ebiom.2019.01.027] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 15.3] [Reference Citation Analysis]
46 Restellini S, Chao CY, Martel M, Barkun A, Kherad O, Seidman E, Wild G, Bitton A, Afif W, Bessissow T, Lakatos PL. Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review. Clin Gastroenterol Hepatol 2019; 17: 1265-1275. e8. [PMID: 30583048 DOI: 10.1016/j.cgh.2018.12.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
47 Domènech E, Panés J, Hinojosa J, Annese V, Magro F, Sturniolo GC, Bossa F, Fernández F, González-Conde B, García-Sánchez V, Dignass A, Herrera JM, Cabriada JL, Guardiola J, Vecchi M, Portela F, Ginard D; ATTICA Study Group by the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa [listed at the end of the article] . Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. J Crohns Colitis 2018;12:687-94. [PMID: 29490024 DOI: 10.1093/ecco-jcc/jjy023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
48 Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. J Crohns Colitis 2019;13:172-81. [PMID: 30285104 DOI: 10.1093/ecco-jcc/jjy149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
49 Panés J, Alfaro I. New treatment strategies for ulcerative colitis. Expert Rev Clin Immunol 2017;13:963-73. [PMID: 28617055 DOI: 10.1080/1744666X.2017.1343668] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
50 Maeda Y, Kudo SE, Mori Y, Misawa M, Ogata N, Sasanuma S, Wakamura K, Oda M, Mori K, Ohtsuka K. Fully automated diagnostic system with artificial intelligence using endocytoscopy to identify the presence of histologic inflammation associated with ulcerative colitis (with video). Gastrointest Endosc. 2019;89:408-415. [PMID: 30268542 DOI: 10.1016/j.gie.2018.09.024] [Cited by in Crossref: 75] [Cited by in F6Publishing: 58] [Article Influence: 18.8] [Reference Citation Analysis]
51 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
52 Ma C, Guizzetti L, Panaccione R, Fedorak RN, Pai RK, Parker CE, Nguyen TM, Khanna R, Vande Casteele N, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther 2018;47:1578-96. [PMID: 29696670 DOI: 10.1111/apt.14672] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
53 Battat R, Vande Casteele N, Pai RK, Wang Z, Zou G, McDonald JWD, Duijvestein M, Jeyarajah J, Parker CE, Van Viegen T, Nelson SA, Boland BS, Singh S, Dulai PS, Valasek MA, Feagan BG, Jairath V, Sandborn WJ. Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. Aliment Pharmacol Ther 2020;52:1574-82. [PMID: 32981088 DOI: 10.1111/apt.16083] [Reference Citation Analysis]
54 Pérez de Arce E, Quera R, Beltrán CJ, Madrid AM, Nos P. Irritable Bowel Syndrome in Inflammatory Bowel Disease. Synergy in alterations of the gut-brain axis? Gastroenterol Hepatol 2021:S0210-5705(21)00143-6. [PMID: 34023477 DOI: 10.1016/j.gastrohep.2021.02.022] [Reference Citation Analysis]
55 Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L. Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. Clin Gastroenterol Hepatol. 2020;18:14-23. [PMID: 31301452 DOI: 10.1016/j.cgh.2019.07.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
56 Colombel JF, Shin A, Gibson PR. AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. Clin Gastroenterol Hepatol. 2019;17:380-390.e1. [PMID: 30099108 DOI: 10.1016/j.cgh.2018.08.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
57 Magro F, Lopes J, Borralho P, Lopes S, Coelho R, Cotter J, Castro FDD, Sousa HTD, Salgado M, Andrade P, Vieira AI, Figueiredo P, Caldeira P, Sousa A, Duarte MA, Ávila F, Silva J, Moleiro J, Mendes S, Giestas S, Ministro P, Sousa P, Gonçalves R, Gonçalves B, Oliveira A, Rosa I, Rodrigues M, Chagas C, Dias CC, Afonso J, Geboes K, Carneiro F. Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels. Gut 2019;68:594-603. [DOI: 10.1136/gutjnl-2017-315545] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 12.3] [Reference Citation Analysis]
58 Turkiewicz J, Bhatt RR, Wang H, Vora P, Krause B, Sauk JS, Jacobs JP, Bernstein CN, Kornelsen J, Labus JS, Gupta A, Mayer EA. Altered brain structural connectivity in patients with longstanding gut inflammation is correlated with psychological symptoms and disease duration. Neuroimage Clin 2021;30:102613. [PMID: 33823388 DOI: 10.1016/j.nicl.2021.102613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
59 Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol 2019;15:667-77. [PMID: 30873890 DOI: 10.1080/1744666X.2019.1593140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
60 Lee J, Park SB, Kim HW, Lee HS, Jee SR, Lee JH, Kim TO, Ricci C. Clinical Efficacy of Probiotic Therapy on Bowel-Related Symptoms in Patients with Ulcerative Colitis during Endoscopic Remission: An Observational Study. Gastroenterology Research and Practice 2022;2022:1-5. [DOI: 10.1155/2022/9872230] [Reference Citation Analysis]
61 Wetwittayakhlang P, Lontai L, Gonczi L, Golovics PA, Hahn GD, Bessissow T, Lakatos PL. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med 2021;10:5551. [PMID: 34884252 DOI: 10.3390/jcm10235551] [Reference Citation Analysis]
62 Furfaro F, Dal Buono A, Allocca M, D'Amico F, Zilli A, Gabbiadini R, Danese S. Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale? Life (Basel) 2021;11:649. [PMID: 34357022 DOI: 10.3390/life11070649] [Reference Citation Analysis]
63 Jairath V, Jeyarajah J, Zou G, Parker CE, Olson A, Khanna R, D'Haens GR, Sandborn WJ, Feagan BG. A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. Lancet Gastroenterol Hepatol 2019;4:63-70. [PMID: 30343116 DOI: 10.1016/S2468-1253(18)30306-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
64 Limketkai BN, Singh S, Jairath V, Sandborn WJ, Dulai PS. US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1828-37. [PMID: 31039246 DOI: 10.1093/ibd/izz081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
65 Monstad IL, Solberg IC, Cvancarova M, Hovde O, Henriksen M, Huppertz-Hauss G, Gunther E, Moum BA, Stray N, Vatn M, Hoie O, Jahnsen J. Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study. J Crohns Colitis 2021;15:969-79. [PMID: 33367569 DOI: 10.1093/ecco-jcc/jjaa232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
66 Dibley L, Czuber-Dochan W, Woodward S, Wade T, Bassett P, Sturt J, Norton C; IBD-DS Patient and Public Involvement Team. Development and Psychometric Properties of the Inflammatory Bowel Disease Distress Scale (IBD-DS): A New Tool to Measure Disease-Specific Distress. Inflamm Bowel Dis 2018;24:2068-77. [PMID: 29788323 DOI: 10.1093/ibd/izy108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
67 Limketkai BN, Sepulveda R, Hing T, Shah ND, Choe M, Limsui D, Shah S. Prevalence and factors associated with gluten sensitivity in inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2018;53:147-51. [DOI: 10.1080/00365521.2017.1409364] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
68 Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol. 2019;114:874-883. [PMID: 30908297 DOI: 10.14309/ajg.0000000000000183] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 33.5] [Reference Citation Analysis]
69 Feagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, Colombel JF. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019; 17: 130-138. e7. [PMID: 29857145 DOI: 10.1016/j.cgh.2018.05.026] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 8.8] [Reference Citation Analysis]
70 Melton E, Qiu H. Interleukin-36 Cytokine/Receptor Signaling: A New Target for Tissue Fibrosis. Int J Mol Sci 2020;21:E6458. [PMID: 32899668 DOI: 10.3390/ijms21186458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]